Skip to main content

Table 3 Tumor response.

From: A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

 

Response evaluation

    

Group

CR

PR

SD

PD

Response rate

Pvalue

Tumor control rate

Pvalue

LG

0

1

9

0

10%

 

100%

 

AG

1

4

8

3

31.3%

0.106

81.3%

0.243

ALG

0

8

7

1

50%

 

93.8%

 
  1. CR: complete remission
  2. PR: partial remission
  3. SD: stable disease
  4. PD: disease progression
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us